Physician

Isaac Melamed, M.D.

According to 2025 Medicare claims, Isaac Melamed, M.D. (NPI: 1366480816) practices allergy/immunology in the Denver-Aurora-Centennial, CO market, with the plurality of this provider's patient population coming from Arapahoe, CO. This provider's primary affiliated billing organization is VEROS CLINICAL SERVICES LLC (NPI: 1134718414; TIN: 854161133) and primary practice location at 80112-1406. Melamed is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Melamed's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 197 traditional Medicare patients, billed 11,898 HCPCS/CPT codes, and received $468,007 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 594 prescription claims across 107 beneficiaries totaling $1,285,571 in drug costs, led by Dupixent Syringe (Dupilumab). 2023 DME data shows 36 claims. Open Payments data shows 111 records totaling $408,918. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $422,400 and ending at $468,007. Concurrently, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $7,232,506 to $1,285,571. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $855 and ending at $1,572.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	109	17,098	$422,400
2016	157	15,537	$374,931
2017	197	36,109	$810,360
2018	202	56,335	$1,525,161
2019	239	42,514	$1,136,378
2020	202	73,251	$1,828,068
2021	182	40,508	$960,243
2022	183	19,860	$591,464
2023	206	14,027	$703,527
2024	197	11,898	$468,007

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	66	552	$7,232,506
2016	75	652	$8,571,413
2017	87	871	$4,567,091
2018	99	872	$5,379,287
2019	103	725	$1,562,572
2020	94	819	$4,038,429
2021	83	658	$2,948,418
2022	92	457	$493,785
2023	102	555	$197,049
2024	107	594	$1,285,571

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	59	$3,709
2016	N/R	11	$285
2017	N/R	105	$5,088
2018	N/R	151	$134,327
2019	N/R	74	$42,478
2020	N/R	37	$37,214
2021	N/R	N/R	N/R
2022	N/R	11	$755
2023	N/R	36	$40,987
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	134	347	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	24	27	$65
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	45	82	$50
96366	Infusion into a vein for therapy, prevention, or diagnosis, each additional hour	38	173	$16
95012	Test to measure the level of nitric oxide gas	37	45	$15

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Dupixent Syringe	Dupilumab	15	448	$60,014
Nitazoxanide	Nitazoxanide	28	651	$18,329
Cromolyn Sodium	Cromolyn Sodium	34	1,485	$7,994
Breo Ellipta	Fluticasone/Vilanterol	14	600	$6,861
Symbicort	Budesonide/Formoterol Fumarate	18	600	$4,681

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	54	$146,711	Octapharma USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	56	$262,207	ACADIA Pharmaceuticals Inc
Ownership / Investment Interests	Reported value of ownership or investment interests.	1	$7,957	Consortium of Independent Immunology Clinics, LLC

Explore More Providers

FAQ

What Medicare data is available for Isaac Melamed, M.D.?

Tedicare shows public-source Medicare data for Isaac Melamed, M.D. (NPI 1366480816), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Isaac Melamed, M.D. have ACO affiliation data?

Isaac Melamed, M.D. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Isaac Melamed, M.D.?

Isaac Melamed, M.D. is linked to VEROS CLINICAL SERVICES LLC (billing NPI 1134718414) in the available physician profile data.

Does Isaac Melamed, M.D. have Open Payments data?

Isaac Melamed, M.D. has 111 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.